Novel targeted therapies focused on specific genetic alterations in individual tumors have opened up a promising new avenue for personalized cancer therapy of colorectal cancer.

The EGF receptor (EGFR) plays a crucial role in colorectal cancer growth. Subsequent to binding of the growth factor EGF to its receptor on the outer surface of the tumor cells, growth signals are transmitted via a molecular cascade to the cell nucleus.

In CRC therapy blocking antibodies to the EGF receptor (Cetuximab/Erbitux™ , Panitumumab/ Vectibix®) have been firmly established. However, only 10% of CRC patients benefit from this kind of immunotherapy.

Main reasons for therapeutic resistance are disturbances in intracellular signal transfer. Key elements of the corresponding molecular cascade are KRAS, BRAF und PIK3CA. These signal transmitters can harbour activating mutations with the consequence of permanent growth stimulation independent of EGF signalling and EGFR antibody blockade.

 We search for activating mutations of KRAS (codon 12, 13. 61 and 146), BRAF (V600E) and PIK3CA (exon 9,20). These mutations can be found in 30-40% (KRAS), 10% (BRAF), and. 15% (PIK3CA).

Test pre-conditions

Formalin-fixed paraffin-embedded tissue is required. Minute tissue quantities (e. g. needle biopsies) are sufficient.

Test duration

Maximum test duration is 7 days.

Logistics

Formalin-fixed paraffin-embedded tumor tissue blocks routinely prepared by the local pathologists are used. These paraffin blocks are usually archived by the pathologist for 10 years. The paraffin embedded tissue is the property of the patient. Thus, the patient has the right of free disposal. On your written request (e-mail) we can take care of the tissue transfer.